Literature DB >> 32469667

Identifying the drivers of patients' reliance on short-acting β2-agonists in asthma.

Sarah Blakeston1, Gavin Harper1, Julen Zabala Mancebo1.   

Abstract

BACKGROUND: One of the most commonly observed asthma treatment patterns is the underuse of inhaled corticosteroid (ICS) maintenance therapy when patients are not experiencing symptoms, and the predominant use of short-acting β2-agonists (SABAs) when patients are experiencing symptoms. This multinational study investigated the current beliefs and behaviors related to reliance on reliever inhalers among asthma patients, and the reasons why patients may not adhere to their recommended maintenance controller treatment.
METHODS: This was a qualitative research study, in which 80 patients with asthma who were receiving reliever therapy (i.e. SABAs) were interviewed, in-depth, for 60 min. The interview questions focused on the patients' experience of living with asthma and their inhaled treatment regimens.
RESULTS: The key insights identified in the interviews were (a) patients had a strong emotional attachment to SABA relievers driven by their efficacy and success in quickly alleviating asthma symptoms, with the reliever also becoming an emotional support; (b) patients typically did not understand that the frequent use of SABAs indicates poor asthma control; (c) patients had a misperception of ICS, which could lead to a delay in escalation and poor adherence; and (d) severe exacerbations improve adherence to ICS, but only temporarily in many cases.
CONCLUSION: This study confirmed the poor level of control patients have over their asthma, and how this affects their lifestyle and daily activities. Our results also confirmed that the patients' perception of both the disease and treatment plays a key role in SABA reliance and ICS underuse.

Entities:  

Keywords:  Asthma; ICS; SABA; adherence; behavior; reliance

Year:  2020        PMID: 32469667     DOI: 10.1080/02770903.2020.1761382

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  5 in total

1.  Clarifying SABA overuse: Translating Canadian Thoracic Society guidelines into clinical practice.

Authors:  Anne K Ellis; Vanessa Foran; Alan Kaplan; Patrick D Mitchell
Journal:  Allergy Asthma Clin Immunol       Date:  2022-06-11       Impact factor: 3.373

2.  It is time to end our love affair with short-acting β2-agonists in asthma.

Authors:  Michael G Crooks; Shoaib Faruqi
Journal:  ERJ Open Res       Date:  2022-10-17

3.  Reducing short-acting beta-agonist overprescribing in asthma: lessons from a quality-improvement prescribing project in East London.

Authors:  Anna De Simoni; Hajar Hajmohammadi; Paul Pfeffer; Jim Cole; Chris Griffiths; Sally A Hull
Journal:  Br J Gen Pract       Date:  2022-06-14       Impact factor: 6.302

4.  Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study.

Authors:  Juliet Foster; Richard Beasley; Irene Braithwaite; Tim Harrison; Mark Holliday; Ian Pavord; Helen Reddel
Journal:  BMJ Open       Date:  2022-01-21       Impact factor: 2.692

5.  High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma.

Authors:  Anna Jetske Baron; Bertine M J Flokstra-de Blok; Huib A M Kerstjens; Gineke Koopmans-Klein; David B Price; Andrea A Sellink; Ioanna Tsiligianni; Janwillem W H Kocks
Journal:  J Asthma Allergy       Date:  2021-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.